Developing a strong patent portfolio is a core pillar of our strategy.

Intellectual Property

Name Issued Pending
CHAPTAC US (US 2015/0266935)
EU (EP 2900697 A)
Japan (JP 533387/2015 A1)
Australia (AU 2013323101 A1)
Canada (CA 2885894 A1)
China
K13 US (US 2012/0269829 A1, US 2016/0074472 A1)
EU (EP 2488637)
Canada (CA 2777628 A1)
China (CN 102666845 A, CN 104740614 A)
Hong Kong (HK 1174944 A)
 
PP-001 US (US 2015/0266935)
EU (EP 2900697 A)
Japan (JP 533387/2015 A1)
China (CN 104797603 A)
Australia (AU 2013323101 A1)
Canada (CA 2885894 A1)
 
PP-002 in stroke US (US 2015/0225704)
EU (EP 2732032 A)
China (CN 103998602 A)
Canada
PP-002 in heart attack   PCT
PP-003 US (US 2015/0266935)
EU (EP 2900697 A)
Japan (JP 533387/2015 A1)
Australia (AU 2013323101 A1)
Canada (CA 2885894 A1)
China,
new US provisional
PP-006   PCT

PP-004 & PP-07: Patent applications in preparation

 

 

Protein-Protein Interference Blockade ] CHAPTAC ] [ Intellectual Property ] Scientific Publications ]